SCHEMBL660324

SCHEMBL660324

Cc1ccc(N2C(=O)NC(=O)C23CCCCC3)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.41
QPCT Q16769 1/20 0.36
POLB P06746 1/20 0.36
AKR1B1 P15121 1/20 0.36
CHRNB2 P17787 1/20 0.35
CHRNA4 P43681 1/20 0.35
ALDH1A1 P00352 1/20 0.33
GLA P06280 1/20 0.33
MAPT P10636 1/20 0.33
DRD3 P35462 1/20 0.33
KCNH2 Q12809 1/20 0.33
PTH1R Q03431 1/20 0.33
MMP13 P45452 2/20 0.32
GRM5 P41594 1/20 0.31
LMNA P02545 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
RIPK1 Q13546 1/20 0.31
EGLN1 Q9GZT9 1/20 0.31
CCNT1 O60563 1/20 0.31
CDK4 P11802 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721033 0.82 CHRNB2 (0.44) CHRNB2CHRNA4ALDH1A1MMP13SMN1; SMN2
SCHEMBL201840 0.80 POLB (0.51) ELANEPOLBAKR1B1ALDH1A1GLA
SCHEMBL719564 0.78 CYP11B1 (0.45) ELANECHRNB2CHRNA4DRD3AR
SCHEMBL421867 0.74 AKR1B1 (0.37) QPCTPOLBAKR1B1ALDH1A1GLA
SCHEMBL17077228 0.74 MAPT (0.45) AKR1B1ALDH1A1MAPTKCNH2NPC1
SCHEMBL190640 0.74 ALDH1A1 (0.55) POLBALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL18961831 0.73 LMNA (0.46) MAPTKCNH2MMP13LMNASMN1; SMN2
SCHEMBL2544529 0.72 MMP13 (0.46) QPCTMAPTKCNH2MMP13LMNA
SCHEMBL20340469 0.70 CYP17A1 (0.37) QPCTPOLBALDH1A1PTH1REGLN1
SCHEMBL422506 0.69 HTT (0.49) ALDH1A1MAPTLMNASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445523-B2 Dioxo-imidazolidine derivatives, which inhibit the enzyme SOAT-1, and pharmaceutical and cosmetic compositions containing them GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-05-21 US disclosed
EP-2401266-B1 NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE SOAT-1 ENZYME, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM GALDERMA RES & DEV (FR) 2012-11-28 EP disclosed
US-20120052096-A1 NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-03-01 US disclosed
US-20120045500-A1 NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052096-A1 NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM SOAT1, SOAT2, ODC1 ELANE 3962/4885QPCT 3283/4885POLB 861/4885
US-20120045500-A1 NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM SOAT1, SOAT2, ODC1 ELANE 3832/4885QPCT 3155/4885POLB 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.